Comparative Pharmacology
Head-to-head clinical analysis: DOLISHALE versus ULTRAM ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOLISHALE versus ULTRAM ER.
DOLISHALE vs ULTRAM ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DOLISHALE is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, enhancing serotonin neurotransmission.
Tramadol is a centrally acting synthetic opioid analgesic that binds to μ-opioid receptors and inhibits serotonin and norepinephrine reuptake.
Adults: 200 mg orally twice daily or 400 mg orally once daily. Administer with food.
100 mg orally once daily initially, titrate up to 100 mg twice daily as needed; maximum 200 mg/day.
None Documented
None Documented
Terminal elimination half-life: 12 hours (range 10-14) in adults; prolonged in renal impairment (up to 24 hours with CrCl <30 mL/min)
The terminal elimination half-life of tramadol is approximately 6.3 hours (range 5-9 hours), while its active metabolite M1 has a half-life of about 7.4 hours. Clinically, this supports dosing every 24 hours for the extended-release formulation.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Renal excretion of tramadol and its metabolites accounts for approximately 90% of total elimination. About 10% is excreted unchanged, 30% as O-desmethyltramadol (M1), and the remainder as other minor metabolites. Biliary/fecal excretion is minimal (<10%).
Category C
Category C
Opioid Analgesic
Opioid Analgesic